Grin Therapeutics is advancing radiprodil, a targeted, selective and potent negative allosteric modulator of the GluN2B subunit of the NMDA receptor, as a therapy for rare neurodevelopmental disorders. Radiprodil has received multiple regulatory designations, including FDA Breakthrough Therapy for seizures associated with GRIN‑NDD with gain‑of‑function variants, FDA Orphan Drug and rare pediatric disease designations, EMA PRIME designation, and a positive EMA CHMP opinion for orphan designation. The company is on track to initiate a global pivotal Phase 3 clinical trial for radiprodil in GRIN‑NDD in Q3 2025, and an ongoing open‑label Phase 1b/2a (Astroscape) study is evaluating the drug in tuberous sclerosis complex and focal cortical dysplasia type II. Grin closed a $140M Series D that included strategic equity and existing investor participation. It has entered a collaboration with Angelini Pharma that grants Angelini commercial rights outside North America while Grin retains the United States, Canada and Mexico rights. Jacopo Andreose, PhD, CEO of Angelini Pharma, will join Grin’s Board of Directors. Under the agreement Grin will receive a $50M upfront payment, will share certain clinical development costs with Angelini, and may receive up to $520M in development, regulatory and sales milestones plus tiered royalties and sublicense payments.

Total raised

$140M

Funding rounds

1

Latest round

Series D

Latest activity

May 2025